Summary
With an accumulated evidence of natural course of patients with hepatitis C virus (HCV) infection, HCV infected patients died from liver-related disease such as liver cirrhosis/liver failure, or hepatocellular carcinoma. Based on these findings, beneficial effect of antiviral therapy for HCV patients is linked to an inhibition of HCC development. Because the difference of disease progression speed and fibrotic stage of the liver may affect the risk of HCC development and efficacy of antiviral therapy depends on virus load, genotype and host factors (age, gender, and fibrotic stage), the benefit of antiviral therapy may differ according to the step of natural course of HCV infection. In spite of improvement of treatment efficacy, antiviral therapy for these patients is still unsatisfactory, but recent studies revealed that retardation of disease progression could be observed after antiviral therapy. Thus, treatment for HCV infected patients should be performed from the standpoint of natural course of HCV infection.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Shiratori Y, Omata M. Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course? J Gastroenterol Hepatol 2000;15:E141–51.
Omata M, Shiratori Y. Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C. J Gastroenterol Hepatol 2000;15:E134–40.
Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, Nakamura A, Asada M, Kuroda H, Tanaka N, Arakawa Y, Omata M. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997;113:558–66.
Shiratori Y, Kato N, Yokosuka O, Hashimoto E, Hayashi N, Nakamura A, Asada M, Kuroda H, Ohkubo H, Arakawa Y, Iwama A, Omata M. Quantitative assays for hepatitis C virus in serum as predictors of the long-term response to interferon. J Hepatol 1997;27:437–44.
Shiratori Y, Kato N, Yoshida H, Imazeki F, Okano K, Yokosuka O, Omata M. How soon can a virological sustained response be determined after withdrawal of interferon therapy in chronic hepatitis C? Tokyo-Chiba Hepatitis Research Group. J Gastroenterol Hepatol 1999;14:79–84.
Shiratori Y, Yokosuka O, Nakata R, Ihori M, Hirota K, Katamoto T, Unuma T, Okano K, Ikeda Y, Hirano M, Kawase T, Takano S, Matsumoto K, Ohashi Y, Omata M. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Hepatology 1999;29:1573–80.
Shiratori Y, Moriyama M, Imazeki F, Ohkubo H, Tanaka N, Arakawa Y, Yoshida H, Yokosuka O, Shibuya A, Matsuzaki K, Hashimoto E, Hayashi N, Hirata K, Ohashi Y, Omata M. A prospective study of interferon therapy modified by pre-treatment viral load in cirrhotic patients. Tokyo-Chiba Hepatitis Research Group. Liver 2000;20:27180.
Shiratori Y, Perelson AS, Weinberger L, Imazeki F, Yokosuka O, Nakata R, Ihori M, Hirota K, Ono N, Kuroda H, Motojima T, Nishigaki M, Omata M. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta. J Hepatol 2000;33:313–22.
Shiratori Y, Kato N, Yoshida H, Nakata R, Ihori M, Imazeki F, Yokosuka O, Kawase T, Katamoto T, Unuma T, Nakamura A, Ikegami F, Hirota K, Omata M. Sustained viral response is rarely achieved in patients with high viral load of HCV RNA by excessive interferon therapy. Dig Dis Sci 2000;45:565–74.
Shiratori Y, Nakata R, Shimizu N, Katada H, Hisamitsu S, Yasuda E, Matsumura M, Narita T, Kawada K, Omata M. High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. IFN-beta Research Group. Dig Dis Sci 2000;45:2414–21.
Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131(7):174–81.
Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, Hamamura K, Imai Y, Yoshida H, Shiina S, Omata M. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology 2000;32:1216–23.
Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y, Yoshida H, Omata M. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138:299–306.
Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517–24.
Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, Yamada G, Yokosuka O, Shiratori Y, Omata M. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002;123:483–91.
Hoshida Y, Shiratori Y, Omata M. Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma. Liver 2002; 22:479–85.
Shiratori Y, Yoshida H, Omata M. Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention. Expert Rev Anticancer Ther 2002; 1:277–90.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Japan
About this paper
Cite this paper
Shiratori, Y. (2004). Roles of Antiviral Therapy in Chronic Hepatitis C Patients Should be Different According to the Stages of Liver Disease Progression. In: Omata, M., Okita, K. (eds) Therapy for Viral Hepatitis and Prevention of Hepatocellular Carcinoma. Springer, Tokyo. https://doi.org/10.1007/978-4-431-53977-3_21
Download citation
DOI: https://doi.org/10.1007/978-4-431-53977-3_21
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-67975-2
Online ISBN: 978-4-431-53977-3
eBook Packages: Springer Book Archive